Please login to the form below

SGLT2 inhibitor

This page shows the latest SGLT2 inhibitor news and features for those working in and with pharma, biotech and healthcare.

AZ data suggest SGLT2 inhibitors can reduce heart failure risk

AZ data suggest SGLT2 inhibitors can reduce heart failure risk. Publishes real-world data for study involving Forxiga/Farxiga, Invokana and Jardiance. ... Real-world evidence has shown that treatment with the newer SGLT2 inhibitor class of diabetes drug

Latest news

Merck & Co and Pfizer take aim at diabetes with trio of new drugs

Merck (known as MSD outside North America) and Pfizer have been working together on ertugliflozin's development since 2013, but are late to the SGLT2 inhibitor party as there are already ... The first SGLT2 inhibitor to be approved in the US was Johnson
AZ gets US approval for diabetes combo Qtern

Qtern is a fixed dose combination product based on the active ingredients in AZ's DPP-4 inhibitor Onglyza (saxagliptin) and SGLT2 inhibitor Farxiga/Forixiga (dapagliflozin). ... The FDA turned down Qtern with a request for more data 16 months ago,
New Jardiance label could boost sales by $1.7bn, says analyst

waited for data from a cardiovascular outcomes trial involving rival SGLT2 inhibitor Invokana (canagliflozin) from Johnson &Johnson, due to report next year. ... Another SGLT1 inhibitor - Bristol-Myers Squibb/AstraZeneca's Forxiga/Farxiga (dapagliflozin)
AstraZeneca's Forxiga set to be recommended by NICE

Currently in the final stages of consultation, the guidance endorses the use of AstraZeneca's SGLT2 inhibitor Forxiga (dapagliflozin) in patients already taking two drugs for blood sugar control without success. ... It has since been backed as a
AZ looks beyond diabetes with Forxiga trials

SGLT2 inhibitor Forxiga (dapagliflozin) is one of AZ's fastest-growing products, with sales rising nearly 90% to $376m in the first half of the year. ... It is however facing intense competition from Boehringer Ingelheim and Eli Lilly's rival SGLT2

More from news
Approximately 1 fully matching, plus 53 partially matching documents found.

Latest Intelligence

Medius Deal Watch table for March 2015

Company acquisition. Marketed BTK inhibitor for haematological cancers pipeline incl. 3 products in clinic. ... 165. Brighthaven Ventures/ Islet Sciences. Licence and collaboration. Phase 2b SGLT2 inhibitor remogliflozin for treatment of diabetes.
Interview: Christopher Boulton, AstraZeneca

Between them, the companies developed the DPP-4 inhibitor Onglyza (saxagliptin), the saxagliptin/metformin combination product Kombiglyze and the SGLT2 inhibitor Forxiga (dapagliflozin), all of which have received approvals in various ... The deal gives
Pharma deals during April 2013

The partnership is to co-develop and commercialise Pfizer's phase III ready oral sodium glucose co-transporter (SGLT2) inhibitor ertugliflozin for the treatment of type 2 diabetes, both as a ... Clearly the pressure is on, the announcement coming only a

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

Pfizer appoints diabetes expert Morris Birnbaum

Pfizer's interests in the area include a collaboration with Merck &Co on the sodium glucose co-transporter (SGLT2) inhibitor ertugliflozin to treat diabetes.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Account Manager / Account Director: Great salary and bebefits

Account Manager – Med Comms – London: Salary TBC

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Senior Account Manager – Med Comms – Kent: Salary TBC

Project Manager, Medical Communications, London: Excellent Salary

Senior Programme Executive: Salary TBC

Scientific Director: Great salary and bebefits

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Editorial Director – Medical Education – Oxford: Negotiable

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Group Account Director, Healthcare Brand Communications, London: Excellent Package

Project Manager, Medical Communications, Oxford: Excellent Salary

Senior Account Manager or AD - Medical Communications: Salary TBC

Medical Writer, e-learning/ training, London: Excellent Salary

Medical Writer - (London, Brighton or Copenhagen): Competitive

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Senior Medical Writer: Great salary and bebefits

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Senior Account Director, Healthcare Brand Communications, London: Excellent Package

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Subscribe to our email news alerts

PMHub

Add my company

Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation: HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...